187 related articles for article (PubMed ID: 30590590)
21. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
[TBL] [Abstract][Full Text] [Related]
22. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
23. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD004115. PubMed ID: 20091560
[TBL] [Abstract][Full Text] [Related]
24. Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases.
Sieber A; Aberra FN; Bonhomme B; McKeever L; Lewis JD
Dig Dis Sci; 2022 Nov; 67(11):5168-5176. PubMed ID: 35094254
[TBL] [Abstract][Full Text] [Related]
25. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
[TBL] [Abstract][Full Text] [Related]
26. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.
Ma C; Guizzetti L; Cipriano LE; Parker CE; Nguyen TM; Gregor JC; Chande N; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2019 Feb; 49(4):364-374. PubMed ID: 30569460
[TBL] [Abstract][Full Text] [Related]
27. Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis.
Barberio B; Gracie DJ; Black CJ; Ford AC
Dig Liver Dis; 2024 Jan; 56(1):7-14. PubMed ID: 37357037
[TBL] [Abstract][Full Text] [Related]
28. Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials.
Shah ED; Siegel CA; Chong K; Melmed GY
Inflamm Bowel Dis; 2016 Apr; 22(4):933-9. PubMed ID: 26818417
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporine A for induction of remission in severe ulcerative colitis.
Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
[TBL] [Abstract][Full Text] [Related]
31. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
[TBL] [Abstract][Full Text] [Related]
32. Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis.
Magro F; Estevinho MM; Dias CC; Correia L; Lago P; Ministro P; Portela F; Feakins R; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 Apr; 15(4):551-566. PubMed ID: 32898223
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and Safety of Tofacitinib for Ulcerative Colitis: Systematic Review and Meta-analysis.
Taneja V; El-Dallal M; Haq Z; Tripathi K; Systrom HK; Wang LF; Said H; Bain PA; Zhou Y; Feuerstein JD
J Clin Gastroenterol; 2022 Nov-Dec 01; 56(10):e323-e333. PubMed ID: 34516458
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set.
Ma C; Panaccione R; Fedorak RN; Parker CE; Nguyen TM; Khanna R; Siegel CA; Peyrin-Biroulet L; D'Haens G; Sandborn WJ; Feagan BG; Jairath V
Clin Gastroenterol Hepatol; 2018 May; 16(5):637-647.e13. PubMed ID: 28843356
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate for induction of remission in ulcerative colitis.
Chande N; MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Oct; (4):CD006618. PubMed ID: 17943916
[TBL] [Abstract][Full Text] [Related]
37. Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis.
Iqbal U; Anwar H; Quadri AA
Am J Med Sci; 2018 Oct; 356(4):350-356. PubMed ID: 30360803
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Chen X; Hou J; Yuan Y; Huang C; Liu T; Mo C; Li H; Chen B; Xu Q; Hou Z; He W; Liu F
BioDrugs; 2016 Jun; 30(3):207-17. PubMed ID: 27120055
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
Zhang ZM; Li W; Jiang XL
Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
